Dexamethasone, a known regulator of mesenchymal programming in glioblastoma (GBM), is routinely used to manage edema in GBM patients. Dexamethasone also activates the expression of genes, such as CEBPB, in GBM stem cells (GSCs). However, the drug’s impact on invasion, proliferation, and angiogenesis in GBM remains unclear. To determine whether dexamethasone induces invasion, proliferation, and angiogenesis in GBM, the authors investigated the drug’s impact in vitro, in vivo, and in clinical information derived from The Cancer Genome Atlas (TCGA) cohort.
Expression profiles of patients from the TCGA cohort with mesenchymal GBM (n = 155) were compared with patients with proneural GBM by comparative marker selection. To obtain robust data, GSCs with IDH1 wild-type (GSC3) and with IDH1 mutant (GSC6) status were exposed to dexamethasone in vitro and in vivo and analyzed for invasion (Boyden chamber, human-specific nucleolin), proliferation (Ki-67), and angiogenesis (CD31). Ex vivo tumor cells from dexamethasone-treated and control mice were isolated by fluorescence activated cell sorting and profiled using Affymetrix chips for mRNA (HTA 2.0) and microRNAs (miRNA 4.0). A pathway analysis was performed to identify a dexamethasone-regulated gene signature, and its relationship with overall survival (OS) was assessed using Kaplan-Meier analysis in the entire GBM TCGA cohort (n = 520).
The mesenchymal subgroup, when compared with the proneural subgroup, had significant upregulation of a dexamethasone-regulated gene network, as well as canonical pathways of proliferation, invasion, and angiogenesis. Dexamethasone-treated GSC3 demonstrated a significant increase in invasion, both in vitro and in vivo, whereas GSC6 demonstrated a modest increase. Furthermore, dexamethasone treatment of both GSC3 and GSC6 lines resulted in significantly elevated cell proliferation and angiogenesis in vivo. Patients with mesenchymal GBM had significant upregulation of dexamethasone-regulated pathways when compared with patients with proneural GBM. A prognostic (p = 0.0007) 33-gene signature was derived from the ex vivo expression profile analyses and used to dichotomize the entire TCGA cohort by high (median OS 12.65 months) or low (median OS 14.91 months) dexamethasone signature.
The authors present evidence that furthers the understanding of the complex effects of dexamethasone on biological characteristics of GBM. The results suggest that the drug increases invasion, proliferation, and angiogenesis in human GSC-derived orthotopic tumors, potentially worsening GBM patients’ prognoses. The authors believe that careful investigation is needed to determine how to minimize these deleterious dexamethasone-associated side effects in GBM.
Correspondence Pascal O. Zinn: Baylor College of Medicine, Houston, TX. firstname.lastname@example.org.
INCLUDE WHEN CITING Published online January 12, 2018; DOI: 10.3171/2017.7.JNS17668.
Disclosures Dr. Sulman: non–study-related clinical support from Novocure and AbbVie. Funding was provided by the following. Dr. Luedi: The Mach-Gaensslen Foundation Neurology Grant 2017 from the Mach-Gaensslen Foundation, Unteraegeri, Switzerland; Alfred & Anneliese Sutter-Stoettner Foundation, Muenchwilen, Switzerland; and Foundation for Research in Anesthesiology and Intensive Care Medicine, Bern, Switzerland. Dr. Colen: John S. Dunn Sr. Distinguished Chair in Diagnostic Imaging and The University of Texas MD Anderson Cancer Center Start-up Fund. Dr. Zinn: Neurosurgery Research & Education Foundation.
FuJ, KhaybullinR, LiangX, MorinM, XiaA, YehA, : Discovery of gene regulation pattern in lung cancer by gene expression profiling using human tissues. 3:112–115, 201510.1016/j.gdata.2014.12.00425664237)| false
HossainAGuminJGaoFFigueroaJShinojimaNTakezakiT: Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. Stem Cells33:2400–24152015
HossainA, GuminJ, GaoF, FigueroaJ, ShinojimaN, TakezakiT, : Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. 33:2400–2415, 20152596666610.1002/stem.2053)| false
MorozMAHuangRKochetkovTShiWThalerHde StanchinaE: Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin Cancer Res17:3282–32922011
MorozMA, HuangR, KochetkovT, ShiW, ThalerH, de StanchinaE, : Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. 17:3282–3292, 20112138592610.1158/1078-0432.CCR-10-3203)| false
Paul-SamojednyMPudełkoASuchanek-RaifRKowalczykMFila-DaniłowABorkowskaP: Knockdown of the AKT3 (PKBγ), PI3KCA, and VEGFR2 genes by RNA interference suppresses glioblastoma multiforme T98G cells invasiveness in vitro. Tumour Biol36:3263–32772015
PhillipsHSKharbandaSChenRForrestWFSorianoRHWuTD: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell9:157–1732006
VerhaakRGHoadleyKAPurdomEWangVQiYWilkersonMD: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell17:98–1102010